Literature DB >> 11484710

Fulminant coxsackieviral myocarditis.

I W Seong, S C Choe, E S Jeon.   

Abstract

Entities:  

Mesh：

Year:  2001        PMID： 11484710     DOI： 10.1056/NEJM200108023450518

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

1.  Effect of interleukin-15 on the course of myocarditis in Coxsackievirus B3-infected BALB/c mice.

Authors:  Boris Bigalke; Peter L Schwimmbeck; Christian S Haas; Stephan Lindemann
Journal:  Can J Cardiol       Date:  2009-07       Impact factor: 5.223

2.  Panax Notoginseng Saponins Ameliorates Coxsackievirus B3-Induced Myocarditis by Activating the Cystathionine-γ-Lyase/Hydrogen Sulfide Pathway.

Authors:  Lulu Pan; Yuanhai Zhang; Jiacheng Lu; Zhimin Geng; Lianhong Jia; Xing Rong; Zhenquan Wang; Qifeng Zhao; Rongzhou Wu; Maoping Chu; Chunxiang Zhang
Journal:  J Cardiovasc Transl Res       Date:  2015-11-02       Impact factor: 4.132

3.  Clinical outcome of acute myocarditis in children according to treatment modalities.

Authors:  Hyun Jung Kim; Gyeong-Hee Yoo; Hong Ryang Kil
Journal:  Korean J Pediatr       Date:  2010-07-31

4.  Cinnamaldehyde Derivatives Inhibit Coxsackievirus B3-Induced Viral Myocarditis.

Authors:  Xiao-Qiang Li; Xiao-Xiao Liu; Xue-Ying Wang; Yan-Hua Xie; Qian Yang; Xin-Xin Liu; Yuan-Yuan Ding; Wei Cao; Si-Wang Wang
Journal:  Biomol Ther (Seoul)       Date:  2017-05-01       Impact factor: 4.634

Review 5.  The Roles of Cardiac Fibroblasts and Endothelial Cells in Myocarditis.

Authors:  Yunling Xuan; Chen Chen; Zheng Wen; Dao Wen Wang
Journal:  Front Cardiovasc Med       Date:  2022-04-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.